SYFOVRE ™ (pegcetacoplan injection) FDA Approval

Conference Call

February 17, 2023





Apellis Participants

CEDRIC FRANCOIS, M.D., Ph.D. *Co-Founder & Chief Executive Officer*

> **CAROLINE BAUMAL, M.D.** *Chief Medical Officer*

ADAM TOWNSEND Chief Commercial Officer

TIM SULLIVAN Chief Financial Officer



Forward Looking Statements

Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding timing of anticipated regulatory submissions Commission. Any forward-looking statements or decisions. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether intravitreal

pegcetacoplan will receive approval from foreign regulatory agencies for GA when expected or at all; and other factors discussed in the "Risk Factors" section of Apellis' Annual Report on Form 10-K with the Securities and Exchange Commission on February 28, 2022 and the risks described in other filings that Apellis may make with the Securities and Exchange contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.



SYFOVRE is approved in the United States!



The **first and only** FDA approved treatment for geographic atrophy secondary to agerelated macular degeneration



SYFOVRE is the only treatment available for GA



2 Flexible dosing options (once every 25-60 days)

3 Indicated for all patients with GA, with or without subfoveal involvement




Well-demonstrated safety profile in ~12,000 injections over 24 months

Label includes positive 24-month efficacy and safety data



SYFOVRE provides comprehensive control of the complement cascade





Source: Merle NS, et al. Cell Research. 2010; 20:34-50.



...for your tireless dedication and unwavering commitment



SYFOVRE is now approved for GA patients in the US



NORMAL VISION



VISION WITH ADVANCED GA






2/3 of GA patients become ineligible to drive within 2 years of diagnosis²



1 Boyer DS et al., Retina 2017 2 Chakravarthy et al. Ophthalmology 2018; 125(6):842-849

Treatment with every-other-month and monthly SYFOVRE resulted in a reduction of GA lesion growth across both studies




SE=standard error: CI=confidence interval

1. SYFOVRE (pegcetacoplan injection) [package insert]. Waltham, MA: Apellis Pharmaceuticals, Inc; 2023. 2. Data on file, Apellis Pharmaceuticals, Inc.

9

SYFOVRE demonstrated increased effects over 24 months



SYFOVRE showed a well-demonstrated safety profile following nearly 12,000 injections

Most common adverse events:

- Ocular discomfort
- Neovascular age related macular degeneration
- Vitreous floaters
- Conjunctival hemorrhage



Rates of endophthalmitis and intraocular inflammation generally in line with those reported in studies of other intravitreal therapies

Rates of ION were higher in monthly compared to every-other-month and sham

No events of occlusive or non-occlusive vasculitis or retinitis were observed




U.S. launch is the first step towards bringing SYFOVRE to GA patients worldwide



- Marketing authorization application (MAA) validated and under review with EMA
- European Commission decision expected early 2024
- Submitted marketing application to Health Canada
- Submissions to Switzerland, Australia, U.K. expected in Q1



Best-in-class team with extensive retina experience ready to launch





Strong value proposition for physicians and patients



Vial price of \$2,190, reflecting SYFOVRE clinical profile and recently approved anti-VEGFs



>90% of patients will be covered by Medicare





We are committed to helping patients obtain access

/ Inclusive insurance support

Financial assistance for eligible patients

Disease education

Dngoing product support





SYFOVRE is approved in the United States!



The **first and only** FDA approved treatment for geographic atrophy secondary to agerelated macular degeneration



Thank you



